The rise of venture capital and biotechnology in the US and Europe

Nature Biotechnology

Volumn 23, Issue 6, 2005, Pages 672-676

  Lee, Douglas P ^a   Dibner, Mark D ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b BioAbility LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUSTRY; MARKETING; SURVEYS; WAXES;

VENTURE CAPITAL;

BIOTECHNOLOGY;

BIOTECHNOLOGY; DRUG INDUSTRY; DRUG MARKETING; EUROPE; FINANCIAL MANAGEMENT; PATENT; PRIORITY JOURNAL; REVIEW; UNITED STATES; ARTICLE; ECONOMICS; INDUSTRY; INTERNATIONAL COOPERATION; INVESTMENT;

BIOTECHNOLOGY; CAPITAL FINANCING; EUROPE; INDUSTRY; INTERNATIONAL COOPERATION; INVESTMENTS; UNITED STATES;

EID: 24944442563     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0605-672     Document Type: Review

References (14)

1. Ernst & Young. Refocus: Ernst & Young's European Biotechnology Report (Ernst and Young, London, 2004).
2. Burrill & Company. Biotech ends on a high note, http:// www.burrillandco.com/burrill/pr_1105471928. Press release, Jan. 5, 2005.
3. European venture-capital investment climbs in first quarter of 2005. Business Wire, May 16 (2005). http://uk.biz.yahoo.com/050515/183/fiv0m.html.
4. th Annual Report on the Industry (Burrill & Company LCC, (San Francisco, CA, USA, 2004).
5. Schuehsler, H. Life science venture capital: a case for Europe. Venture Capital Journal 44, 60-62, 2004.
6. Collins, S.W. The Race to Commercialize Biotechnology: Molecules, Markets and the State in the United States and Japan (RoutledgeCurzon, London, 2004).
7. PricewaterhouseCoopers/Thomson, Venture Economics and National Venture Capital Association MoneyTree Survey. Full-year & Q4 2004 results. US Report, January 3, 2005. http://www.pwcmoneytree.com/ exhibits/ 04Q4MoneyTreeReport.pdf.
8. PricewaterhouseCoopers/Thompson, Venture Economics and National Venture Capital Association MoneyTree Survey. Venture capital investing settles back to $4.6 billion in 2005. MoneyTree Survey, http://www.pwcmoneytree.com/ exhibits/ 05Q1SurveyHighlights.pdf.
9. Howell, M., Trull, M. & Dibner, M. The rise of European venture capital for biotechnology. Nat. Biotechnol. 21, 1287-1291 (2003).
10. BioAbility, European Biotechnology Venture Capital Database (Thomson, Bioworld, Atlanta, GA, USA, 2005).
11. BioAbility, US/Canadian Biotechnology Venture Capital Database (Thomson BioWorld Atlanta, GA, USA, 2005).
12. European Private Equity & Venture Capital Association. Benchmark Paper: Benchmarking European Tax and Legal Environments. (Brussels, Belgium May 2004). http://www.evca.com/images/attachments/tmpl_9_art. 90_att_587.pdf.
13. Flanigan, J. Foreign funding blooms for tech in US. Los Angeles Times, April 4 2004, p. C1.
14. Ernst & Young, SWX Swiss Exchange, the State Secretariat for Economic Affairs, the innovation promotion agency KTI/CTI, and Swiss Biotech. Swiss Biotech Report. (March 11, 2004). (http://www2.eycom.ch/ publications/items/ biotech_swissreport/en.pdf).